Vir Biotechnology, Inc. (NASDAQ:VIR) Q1 2024 Earnings Call Transcript

Carrie Huang: All right, thank you for the question. So we do have this ongoing trial with VIR 1388, which is our HCMV vector as a potential HIV vaccine. And this is in partnership with the HVTM, who is helping us conduct the trial. And we have completed enrollment of part a of that trial. And as we’ve guided to, we expect to see initial immunologic data from that trial second half of this year. And so what we are really looking for is these immunologic endpoints, specifically looking at T cell markers and MHC restricted kind of T cell responses, and kind of seeing what we would see if we see similar types of immune responses that were observed in the macaques that were protective from SIV in those animals. And so if we’re able to see this proof of immunology, then this opens up this platform to other areas, potential areas of exploration, such as in human papillomavirus with our VIIR 1949 vector.

Operator: There are no further questions at this time. I will now turn the conference back over to Marianne for the closing remarks.

Marianne De Backer: Thank you. Operator. To conclude, our company is beginning to realize benefits from the cost savings initiatives we implemented in 2023, and we look forward to sharing important data from our SOLSTICE trial at easel. This is a milestone that brings us closer to addressing the significant unmet medical need for millions of people that are living with hepatitis Delta. Looking ahead, we also anticipate additional data readouts in the fourth quarter that could serve as important catalyst for the company. Thank you. And operator, you may conclude the call. Thank you.

Operator: That concludes today’s call. Thank you all for joining. You may now disconnect.